SEP 27, 2019 9:00 AM PDT

Investigating how Tpz-1 may be used as a novel therapeutic agent in the treatment of human hematologic cancers

Speaker

Abstract
DATE:  September 27, 2019
TIME:   9:00am PT, 12:00pm ET
 
Thienopyrazole derivatives have recently emerged as effective antitumoral agents with kinase inhibitory activity.  In this study, a novel thienopyrazole derivative with potent and selective in vitro cytotoxicity was identified in a high-throughput chemical library screening to identify novel anti-cancer drugs.  After 48 hours of exposure, compound Tpz-1 demonstrated potent and consistent cytotoxicity against a panel of human hematologic cells at nanomolar to low micromolar concentrations; an effect which was greatly diminished against the HS-27 non-cancerous foreskin fibroblast cell line.  Mechanistic analyses subsequently conducted against the CEM T-cell leukemia cell line revealed that Tpz-1 induces cell death via apoptosis and interferes with cell cycle progression in a dose-dependent manner.  These findings merit the further development of Tpz-1 as a novel therapeutic agent in the treatment of human hematologic cancers.
 
In this webinar you will learn:
  • to investigate the mechanism, Tpz-1, through a series of apoptosis assays and a transcriptome analysis
  • Tpz-1 activity against leukemia and lymphoma cell lines and normal cell types.
 
 
 
 
Webinars will be available for unlimited on-demand viewing after live event.
 
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

Show Resources
SEP 27, 2019 9:00 AM PDT

Investigating how Tpz-1 may be used as a novel therapeutic agent in the treatment of human hematologic cancers



Show Resources
Show Resources
Connect with us